490 related articles for article (PubMed ID: 26155041)
21. Consensus Statement of HCV Task Force of the Indian National Association for Study of the Liver (INASL). Part II: INASL Recommendations for Management of HCV in India.
Puri P; Anand AC; Saraswat VA; Acharya SK; Sarin SK; Dhiman RK; Aggarwal R; Singh SP; Amarapurkar D; Arora A; Chhabra M; Chetri K; Choudhuri G; Dixit VK; Duseja A; Jain AK; Kapoor D; Kar P; Koshy A; Kumar A; Madan K; Misra SP; Prasad MV; Nagral A; Puri AS; Jeyamani R; Saigal S; Shah S; Sharma PK; Sood A; Thareja S; Wadhawan M
J Clin Exp Hepatol; 2014 Jun; 4(2):117-40. PubMed ID: 25755549
[TBL] [Abstract][Full Text] [Related]
22. Sustained virological response to pegylated interferon and ribavirin in patients with genotype 3 HCV cirrhosis.
Butt AS; Mumtaz K; Aqeel I; Shah HA; Hamid S; Jafri W
Trop Gastroenterol; 2009; 30(4):207-12. PubMed ID: 20426280
[TBL] [Abstract][Full Text] [Related]
23. Optimal Duration of Pegylated Interferon Plus Ribavirin Therapy for Chronic Hepatitis C Genotype 3 Patients who do not Achieve Rapid Virological Response.
Sood A; Midha V; Goyal O
J Clin Exp Hepatol; 2015 Mar; 5(1):2-7. PubMed ID: 25941428
[TBL] [Abstract][Full Text] [Related]
24. Response to pegylated interferon plus ribavirin among HIV/hepatitis C virus-coinfected patients with compensated liver cirrhosis.
Mira JA; García-Rey S; Rivero A; de los Santos-Gil I; López-Cortés LF; Girón-González JA; Téllez F; Márquez M; Merino D; Ríos-Villegas MJ; Macías J; Rivero-Juárez A; Pineda JA
Clin Infect Dis; 2012 Dec; 55(12):1719-26. PubMed ID: 22955435
[TBL] [Abstract][Full Text] [Related]
25. Hepatocellular Carcinoma Mechanisms Associated with Chronic HCV Infection and the Impact of Direct-Acting Antiviral Treatment.
Dash S; Aydin Y; Widmer KE; Nayak L
J Hepatocell Carcinoma; 2020; 7():45-76. PubMed ID: 32346535
[TBL] [Abstract][Full Text] [Related]
26. Sustained virologic response by direct antiviral agents reduces the incidence of hepatocellular carcinoma in patients with HCV infection.
Kobayashi M; Suzuki F; Fujiyama S; Kawamura Y; Sezaki H; Hosaka T; Akuta N; Suzuki Y; Saitoh S; Arase Y; Ikeda K; Kumada H
J Med Virol; 2017 Mar; 89(3):476-483. PubMed ID: 27531586
[TBL] [Abstract][Full Text] [Related]
27. Improved survival of patients with hepatocellular carcinoma and compensated hepatitis C virus-related cirrhosis who attained sustained virological response.
Bruno S; Di Marco V; Iavarone M; Roffi L; Boccaccio V; Crosignani A; Cabibbo G; Rossi S; Calvaruso V; Aghemo A; Giacomelli L; Craxì A; Colombo M; Maisonneuve P
Liver Int; 2017 Oct; 37(10):1526-1534. PubMed ID: 28418617
[TBL] [Abstract][Full Text] [Related]
28. Telaprevir for HIV/hepatitis C virus-coinfected patients failing treatment with pegylated interferon/ribavirin (ANRS HC26 TelapreVIH): an open-label, single-arm, phase 2 trial.
Cotte L; Braun J; Lascoux-Combe C; Vincent C; Valantin MA; Sogni P; Lacombe K; Neau D; Aumaitre H; Batisse D; de Truchis P; Gervais A; Michelet C; Morlat P; Vittecoq D; Rosa I; Bertucci I; Chevaliez S; Aboulker JP; Molina JM;
Clin Infect Dis; 2014 Dec; 59(12):1768-76. PubMed ID: 25139963
[TBL] [Abstract][Full Text] [Related]
29. [Antiviral treatment and long-term clinical outcome of decompensated cirrhotic patients with hepatitis C virus infection].
Ji F; Dang S; Cai Z; Xue H; Huang N; Liu L; Zhang S; Guo Y; Jia X; Wang Y; Li Z; Deng H
Zhonghua Gan Zang Bing Za Zhi; 2015 Sep; 23(9):647-52. PubMed ID: 26524356
[TBL] [Abstract][Full Text] [Related]
30. Boceprevir plus pegylated interferon/ribavirin to re-treat hepatitis C virus genotype 1 in HIV-HCV co-infected patients: final results of the Spanish BOC HIV-HCV Study.
Laguno M; Von Wichmann MA; Van den Eynde E; Navarro J; Cifuentes C; Murillas J; Veloso S; Martínez-Rebollar M; Guardiola JM; Jou A; Gómez-Sirvent JL; Cervantes M; Pineda JA; López-Calvo S; Carrero A; Montes ML; Deig E; Tapiz A; Ruiz-Mesa JD; Cruceta A; de Lazzari E; Mallolas J
Int J Infect Dis; 2016 Dec; 53():46-51. PubMed ID: 27815225
[TBL] [Abstract][Full Text] [Related]
31. Post-treatment levels of α-fetoprotein predict incidence of hepatocellular carcinoma after interferon therapy.
Oze T; Hiramatsu N; Yakushijin T; Miyazaki M; Yamada A; Oshita M; Hagiwara H; Mita E; Ito T; Fukui H; Inui Y; Hijioka T; Inada M; Katayama K; Tamura S; Yoshihara H; Inoue A; Imai Y; Hayashi E; Kato M; Miyagi T; Yoshida Y; Tatsumi T; Kasahara A; Hamasaki T; Hayashi N; Takehara T;
Clin Gastroenterol Hepatol; 2014 Jul; 12(7):1186-95. PubMed ID: 24321207
[TBL] [Abstract][Full Text] [Related]
32. A polymorphism in interferon L3 is an independent risk factor for development of hepatocellular carcinoma after treatment of hepatitis C virus infection.
Chang KC; Tseng PL; Wu YY; Hung HC; Huang CM; Lu SN; Wang JH; Lee CM; Chen CH; Tsai MC; Yen YH; Lin MT; Wu CK; Huang CC; Chen HH; Hu TH
Clin Gastroenterol Hepatol; 2015 May; 13(5):1017-24. PubMed ID: 25460552
[TBL] [Abstract][Full Text] [Related]
33. A multidisciplinary support programme increases the efficiency of pegylated interferon alfa-2a and ribavirin in hepatitis C.
Carrión JA; Gonzalez-Colominas E; García-Retortillo M; Cañete N; Cirera I; Coll S; Giménez MD; Márquez C; Martin-Escudero V; Castellví P; Navinés R; Castaño JR; Galeras JA; Salas E; Bory F; Martín-Santos R; Solà R
J Hepatol; 2013 Nov; 59(5):926-33. PubMed ID: 23811030
[TBL] [Abstract][Full Text] [Related]
34. Advanced hepatic fibrosis and steatosis are associated with persistent alanine aminotransferase elevation in chronic hepatitis C patients negative for hepatitis C virus RNA during pegylated interferon plus ribavirin therapy.
Liang CC; Liu CH; Chung CS; Lin CK; Su TH; Yang HC; Liu CJ; Chen PJ; Chen DS; Kao JH
J Infect Dis; 2015 May; 211(9):1429-36. PubMed ID: 25387585
[TBL] [Abstract][Full Text] [Related]
35. INASL Position Statements on Prevention, Diagnosis and Management of Hepatitis B Virus Infection in India: The Andaman Statements.
Arora A; Singh SP; Kumar A; Saraswat VA; Aggarwal R; Bangar M; Bhaumik P; Devarbhavi H; Dhiman RK; Dixit VK; Goel A; Goswami B; Kapoor D; Madan K; Narayan J; Nijhawan S; Pandey G; Rai RR; Sahu MK; Saraf N; Shalimar ; Shenoy T; Thomas V; Wadhawan M;
J Clin Exp Hepatol; 2018 Mar; 8(1):58-80. PubMed ID: 29743798
[TBL] [Abstract][Full Text] [Related]
36. [Discussion on optimal duration of pegylated interferon α combined with ribavirin for chronic hepatitis C in HIV-infected patients].
Ke YC; Li LH; Hu FY; Lan Y; He YZ; Chen XJ; Tang XP; Cai WP; Lu RC; He Y; Li HQ
Zhonghua Gan Zang Bing Za Zhi; 2018 Apr; 26(4):282-287. PubMed ID: 29996340
[No Abstract] [Full Text] [Related]
37. Treatment of chronic genotype-3 hepatitis C virus infection using direct-acting antiviral agents: An Indian experience.
Goel A; Bhargava R; Rai P; Aggarwal R
Indian J Gastroenterol; 2017 May; 36(3):227-234. PubMed ID: 28656492
[TBL] [Abstract][Full Text] [Related]
38. Phase III results of Boceprevir in treatment naïve patients with chronic hepatitis C genotype 1.
Manns MP; Markova AA; Calle Serrano B; Cornberg M
Liver Int; 2012 Feb; 32 Suppl 1():27-31. PubMed ID: 22212568
[TBL] [Abstract][Full Text] [Related]
39. Territory-wide population-based study of chronic hepatitis C infection and implications for hepatitis elimination in Hong Kong.
Hui YT; Wong GLH; Fung JYY; Chan HLY; Leung NWY; Liu SD; Liu K; Ma YK; But DYK; Mak WY; Chan JMC; Lai KB; Loo CK; Ng ACY; Lai MS; Chan CW; Lau JYL; Fan TTT; Hui AJ; Lam BCY; Cheung WI; Tsang OTY; Lam K; Lai LSW; Luk WF; Li MKK; Lao WC; Lam JTW; Tsang SWC; Kung KN; Chow WH; Tong RKN; Lui TKL; Shan EHS; Yuen MF; Wong VWS
Liver Int; 2018 Nov; 38(11):1911-1919. PubMed ID: 29981176
[TBL] [Abstract][Full Text] [Related]
40. Impaired response to interferon-alpha2b plus ribavirin in cirrhotic patients with genotype 3a hepatitis C virus infection.
Aghemo A; Rumi MG; Soffredini R; D'Ambrosio R; Ronchi G; Del Ninno E; Gallus S; Colombo M
Antivir Ther; 2006; 11(6):797-802. PubMed ID: 17310824
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
